Clinical trials: Age-Related Maculopathy
Neovascular Age-related Macular Degeneration
Efficacy And Safety Of Macugen In Patients With Neovascular AMD In Routine Clinical Practice.
Efficacy and safety of MACUGEN in patients suffering from neovascular age-related macular degeneration in routine clinical practice at least as good as demonstrated in randomized multicenter clinical trials.
- Trial name
- MACULA (NCT00858208)
- Testing
- pegaptanib sodium
- Where
- 8 sites in Greece
- Volunteers
- 86 people
- Sponsor
- Pfizer
Age-Related Macular Degeneration (AMD), Non-Neovascular Age-Related Macular Degeneration
Long-Term Follow Up of VOY-101 Non-nAMD Extension Study
Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration
- Trial name
- OASIS (NCT07660640)
- Testing
- observational study, VOY-101
- Where
- 4 sites in United States, Israel
- Volunteers
- 88 people
- Sponsor
- Perceive Biotherapeutics, Inc.
Retinal Disease
Study to Gather Information on the Safety and Use of Aflibercept Injections Into the Eye for the Treatment of Eye Disorders in Mexican Routine Clinical Practice
The study aims to collect data on the safety and use of intravitreal aflibercept injections into the eye for the treatment of eye disorders that cause blurred vision or a blind spot due to abnormal or blocked blood vessels.
- Trial name
- MAIA (NCT04137120)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- Mexico
- Volunteers
- 73 people
- Sponsor
- Bayer
Macular Degeneration
Vision Improvement for Patients With Age-Related Macular Degeneration
This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.
- Trial name
- NCT06198452
- Testing
- Vision Improvement
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- VIS, Inc.
Dry Age-related Macular Degeneration
Study of Photobiomodulation to Treat Dry Age-Related Macular Degeneration (LIGHTSITE III)
This LIGHTSITE III study is a double-masked, sham-controlled, parallel design, prospective multi-site study for the use of PBM as a treatment for visual impairment in subjects with dry AMD.
- Trial name
- NCT04065490
- Testing
- Valeda Light Delivery System
- Where
- 10 sites in United States
- Volunteers
- 100 people
- Sponsor
- LumiThera, Inc.
Wet Age Related Macular Degeneration
Phase 3 Study of Intravitreal OLN324 in Adults With Neovascular (Wet) Age-related Macular Degeneration (nAMD) (OLN324-CP-04)
This is a Phase 3 study of an investigational drug called OLN324, which is being developed by Ollin Biosciences as a treatment for patients with neovascular (wet) age-related macular degeneration (nAMD).
- Trial name
- MOJAVE (NCT07816315)
- Testing
- OLN324, Aflibercept
- Volunteers
- 500 people
- Sponsor
- Ollin Biosciences, Inc.
Age-Related Macular Degeneration, Choroidal Neovascularization
Phase 2 Study of an Ocular Sirolimus (Rapamycin) Formulation in Combination With Lucentis® in Patients With Age-Related Macular Degeneration
The purpose of this study is to determine the safety and efficacy of an ocular sirolimus (rapamycin) formulation in combination with Lucentis in patients with sub-foveal choroidal neovascularization secondary to age-related…
- Trial name
- EMERALD (NCT00766337)
- Testing
- Sirolimus in combination with ranibizumab
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Santen Inc.
Macular Degeneration
Randomized, Single-Masked, Long-Term, Safety and Tolerability Study of VEGF Trap-Eye in AMD
Rollover study for subjects in prior VEGF Trap-Eye Phase I and II studies. Primary objective is to assess long-term safety and tolerability of continuing intravitreal treatment in subjects with wet age-related macular…
- Trial name
- NCT00527423
- Testing
- VEGF Trap Eye
- Where
- 33 sites in United States
- Volunteers
- 157 people
- Sponsor
- Regeneron Pharmaceuticals
Diabetic Macular Edema, Neovascular Age-related Macular Degeneration
A Study to Learn About the Blood Levels of Aflibercept When High-dose Aflibercept is Injected in Both Eyes of Participants With Diabetic Macular Edema or Neovascular Age-related Macular Degeneration
Researchers are looking for a better way to treat participants who have diabetic macular edema (DME) or neovascular age-related macular degeneration (nAMD). DME is a diabetes-related eye disorder.
- Trial name
- DEUTERON (NCT06591598)
- Testing
- Aflibercept (BAY86-5321, Eylea)
- Where
- 6 sites in Czechia, Hungary and 1 more
- Volunteers
- 51 people
- Sponsor
- Bayer
Geographic Atrophy
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
This study is open to adults aged 50 years and older with geographic atrophy that was diagnosed by imaging of the retina. The purpose of this study is to find out whether a medicine called BI 1584862 improves the eyes in people…
- Trial name
- NCT06769048
- Testing
- BI 1584862
- Where
- 44 sites in United States, Puerto Rico
- Volunteers
- 150 people
- Sponsor
- Boehringer Ingelheim
Wet Macular Degeneration, Neovascular Age-related Macular Degeneration
A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.
- Conditions
- Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
- Trial name
- NCT05637255
- Testing
- SYL1801
- Where
- 16 sites in Czechia, Poland and 1 more
- Volunteers
- 99 people
- Sponsor
- Sylentis, S.A.
Neovascular Age-Related Macular Degeneration
Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection
The primary objective of the study is to compare the efficacy of intravitreal (IVT)-administered REGN910-3 compared to intravitreal aflibercept injection (IAI).
- Trial name
- ONYX (NCT02713204)
- Testing
- REGN910-3, Intravitreal Aflibercept Injection (IAI)
- Where
- 87 sites in United States
- Volunteers
- 365 people
- Sponsor
- Regeneron Pharmaceuticals
Wet Age-related Macular Degeneration
A Study to Compare QL1207 to Eylea® in Subjects With Wet Age-related Macular Degeneration (wAMD)
This is a randomised, double-masked, parallel group, multicentre study to evaluate the efficacy and safety of QL1207 compared to Eylea® in subjects with wet AMD.
- Trial name
- NCT05345236
- Testing
- Aflibercept
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Age-Related Macular Degeneration, Wet Macular Degeneration
An Open-label Study to Evaluate the Clinical and Economic Benefits of I-Ray in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration
The purpose of this study is to confirm the clinical and economic benefits of IRay treatment with respect to the number of anti-VEGF injections and frequency of visits during the first year after treatment for patients with wet…
- Conditions
- Age-Related Macular Degeneration, Wet Macular Degeneration, Macular Degeneration, Eye Diseases
- Trial name
- ENDEAVOUR (NCT01521065)
- Testing
- IRay
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Oraya Therapeutics, Inc.
Neovascular Age-Related Macular Degeneration (nAMD)
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
This is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal…
- Trial name
- NCT05210803
- Testing
- Standard of Care, Ranibizumab
- Where
- 16 sites in United States
- Volunteers
- 116 people
- Sponsor
- AbbVie
Wet Age-related Macular Degeneration
A Long-term Follow up Study of EXG102-031 in Participants With wAMD
This is a long-term, safety and efficacy follow-up study of patients in the EXG102-031-111 gene therapy clinical trial for wAMD.
- Trial name
- NCT06859515
- Testing
- No intervention, only for observational studies
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Guangzhou Jiayin Biotech Ltd
Geographic Atrophy
A Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration
This is a 24-month, Phase III, multicenter, randomized, double-masked, sham-injection controlled study to assess the efficacy and safety of multiple IVT injections of APL-2 in subjects with GA secondary to AMD.
- Trial name
- NCT03525613
- Testing
- APL-2
- Where
- 112 sites in United States, Australia and 12 more
- Volunteers
- 637 people
- Sponsor
- Apellis Pharmaceuticals, Inc.
Wet Age-related Macular Degeneration
Clinical Study on the Efficacy and Safety of BAT5906 Injection
This study is a multi-center, open, and phase II clinical study to evaluate the efficacy and safety of BAT5906 injection in patients with wet age-related macular degeneration.
- Trial name
- NCT05141994
- Testing
- 2.5mg of BAT5906, 4mg of BAT5906
- Where
- 16 sites in China
- Volunteers
- 48 people
- Sponsor
- Bio-Thera Solutions
Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
This is an observational study in which data already collected from people with the eye disorders below are studied. In observational studies, only observations are made without participants receiving any advice or any changes to…
- Trial name
- AIRSPEED (NCT06495203)
- Testing
- anti-VEGF treatment
- Where
- Canada
- Volunteers
- 1,350 people
- Sponsor
- Bayer
Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
This is a multi-center, randomized, double-masked, active-comparator-controlled, Phase 3 study in a broad participant population (treatment-naïve and treatment-experienced) with neovascular (wet) age-related macular degeneration…
- Trial name
- ARTEMIS (NCT06856577)
- Testing
- Ixo-vec, Aflibercept
- Where
- 75 sites in United States
- Volunteers
- 311 people
- Sponsor
- Adverum Biotechnologies, Inc.